MedTrace Logo

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

NCT03448835 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-08

No results posted yet for this study

Summary

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.

The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

Conditions

  • Stomach Cancer
  • Gastro Esophageal Junction Cancer

Interventions

DRUG

Atezolizumab

atezolizumab 1200 mg 5 cycles

DRUG

Capecitabine

capecitabine 850 mg /m2 4 cycles

DRUG

Oxaliplatin

oxaliplatin 100 mg/m2 4 cycles

DRUG

Docetaxel

docetaxel 50 mg/m2 4 cycles

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Myriam Chalabi, MD · Antoni van Leeuwenhoek

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03448835 on ClinicalTrials.gov